Introduction

This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Allergan's performance against key rivals in the prescription pharmaceutical sector

*Assess how the key Botox franchise stands up to the global recession and the arrival of further competitors

*Analyze the impact of Allergan's acquisition of Esprit Pharma in 2007, namely its movement into the urology therapy market

Report Highlights

[Studien Infos ausblenden]

List of Tables
Table 1: Allergan - PharmaVitae forecasts at a glance 8
Table 2: Allergan key product developments, Q1-Q2 2009 19
Table 3: Allergan product deals and alliances, Q1-Q2 2009 20
Table 4: Allergan technology deals and alliances, Q1-Q2 2009 21
Table 5: Allergan M&A activity, Q1-Q2 2009 21
Table 6: Allergan company announcements, Q1-Q2 2009 22
Table 7: Allergan future product milestones, 2009-11 22
Table 8: Allergan product portfolio overview ($m), 2002-08 35
Table 9: Allergan product portfolio overview ($m), 2008-14 37
Table 10: Allergan prescription pharmaceutical sales by therapy area ($m), 2008-14 42
Table 11: Allergan prescription pharmaceutical sales by geographic region ($m), 2008-14 44
Table 12: Allergan launch portfolio overview ($m), 2008-14 46
Table 13: Allergan core portfolio overview ($m), 2008-14 49
Table 14: Allergan expiry portfolio overview ($m), 2008-14 50
Table 15: Allergan prescription pharmaceutical sales by molecule type ($m), 2008-14 54
Table 16: Allergan prescription pharmaceutical sales by source ($m), 2008-14 56
Table 17: Total Allergan sales by business unit ($m), 2002-08 58
Table 18: Allergan operating revenue/cost analysis ($m), 2002-08 61
Table 19: Allergan operating cost ratio analysis (% of total revenues), 2002-08 62
Table 20: Allergan operating cost ratio analysis (% of total revenues), 2008-14 63
Table 21: Allergan operating revenue/cost analysis ($m), 2008-14 64
Table 22: Key products overview 67
Table 23: Botox: overview 68
Table 24: Botox: sales forecast ($m), 2008-14 69
Table 25: Restasis: overview 71
Table 26: Restasis: sales forecast ($m), 2008-14 72
Table 27: Lumigan franchise: overview 73
Table 28: Lumigan franchise: sales forecast ($m), 2008-14 74
Table 29: Alphagan franchise: overview 76
Table 30: Alphagan franchise: sales forecast ($m), 2008-14 77
Table 31: Ozurdex: overview 79
Table 32: Ozurdex: sales forecast ($m), 2008-14 80
Table 33: Latisse: overview 82
Table 34: Latisse: sales forecast ($m), 2008-14 83
Table 35: Allergan's R&D pipeline (Phase I-registration) 84
Table 36: Total Allergan revenue by business unit and product line ($m), 2002-08 85
Table 37: Exchange rates, 2009 87
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Allergan's financial performance ($m), 2002-14 7
Figure 4: Allergan prescription pharmaceutical sales ($m), 2002-14 9
Figure 5: The central role of Botox in Allergan's strategic moves 10
Figure 6: Allergan SWOT analysis 12
Figure 7: Allergan's M&A history 25
Figure 8: Current corporate structure 29
Figure 9: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 32
Figure 10: Key product sales ($m), 2002-14 34
Figure 11: Allergan key sales growth drivers and resistors ($m), 2002-08 36
Figure 12: Allergan key sales growth drivers and resistors ($m), 2008-14 38
Figure 13: Allergan prescription pharmaceutical sales by therapy area ($m), 2002-14 40
Figure 14: Allergan prescription pharmaceutical sales by geographic region ($m), 2002-14 43
Figure 15: Allergan launch/core/expiry configuration ($m), 2008-14 52
Figure 16: Allergan prescription pharmaceutical sales by molecule type ($m), 2002-14 53
Figure 17: Allergan prescription pharmaceutical sales by source ($m), 2002-14 55
Figure 18: Allergan operating revenue/cost analysis ($m), 2002-14 60
Figure 19: Mechanisms by which current treatments reduce intraocular pressure 75
[Tabellenverzeichnis ausblenden]